TYPE: Specialised
BRAND: Biluta
ACTIVE INGREDIENT: Bicalutamide
STRENGTH & PACK SIZE & GMS CODES:
50 mg Film-coated tablets x 28 ~ 88721
INDICATION:
Combination therapy with Biluta 50 mg:
Treatment of advanced prostate cancer in combination with luteinizing hormone-releasing hormone (LHRH) analogue therapy or surgical castration.
Monotherapy with 3 tablets of Biluta 50 mg (150 mg bicalutamide):
Biluta at a dose of 150 mg is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression.
Download Biluta 50mg SPC and Patient Information Leaflet here
